Kevin Kai Hill

Array ( [id] => 12786316 [patent_doc_number] => 20180153941 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-07 [patent_title] => METHODS FOR GENERATING STEM CELL-DERIVED BETA CELLS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 15/666555 [patent_app_country] => US [patent_app_date] => 2017-08-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10804 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15666555 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12137091 [patent_doc_number] => 20180015174 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-01-18 [patent_title] => 'SYNTHETIC NANOPARTICLES FOR DELIVERY OF IMMUNOMODULATORY COMPOUNDS' [patent_app_type] => utility [patent_app_number] => 15/650177 [patent_app_country] => US [patent_app_date] => 2017-07-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 21093 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 14 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15650177 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12157334 [patent_doc_number] => 20180028600 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-01 [patent_title] => 'NOVEL RECOMBINANT EXOSOME AND USE THEREOF' [patent_app_type] => utility [patent_app_number] => 15/650272 [patent_app_country] => US [patent_app_date] => 2017-07-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 8308 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15650272 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16177197 [patent_doc_number] => 20200224165 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-16 [patent_title] => METHODS AND COMPOSITIONS FOR REJUVENATION [patent_app_type] => utility [patent_app_number] => 16/319517 [patent_app_country] => US [patent_app_date] => 2017-07-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7183 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 79 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16319517 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14682477 [patent_doc_number] => 20190240353 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-08 [patent_title] => AAV2-MEDIATED GENE DELIVERY OF SFASL AS A NEUROPROTECTIVE THERAPY IN GLAUCOMA [patent_app_type] => utility [patent_app_number] => 16/315362 [patent_app_country] => US [patent_app_date] => 2017-07-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17099 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16315362 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12022199 [patent_doc_number] => 20170312299 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-02 [patent_title] => 'Cellular Delivery of DNA Intercalating Agents' [patent_app_type] => utility [patent_app_number] => 15/631226 [patent_app_country] => US [patent_app_date] => 2017-06-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 5997 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15631226 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13104011 [patent_doc_number] => 10070631 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-09-11 [patent_title] => Rodents having a humanized TMPRSS gene [patent_app_type] => utility [patent_app_number] => 15/624774 [patent_app_country] => US [patent_app_date] => 2017-06-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 13 [patent_no_of_words] => 16165 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 101 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15624774 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12656701 [patent_doc_number] => 20180110733 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-04-26 [patent_title] => METHODS AND COMPOSITIONS FOR LOCALIZED AGENT DELIVERY [patent_app_type] => utility [patent_app_number] => 15/625479 [patent_app_country] => US [patent_app_date] => 2017-06-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24480 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15625479 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12031114 [patent_doc_number] => 20170321214 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-09 [patent_title] => 'DEAD GUIDES FOR CRISPR TRANSCRIPTION FACTORS' [patent_app_type] => utility [patent_app_number] => 15/620391 [patent_app_country] => US [patent_app_date] => 2017-06-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 37 [patent_figures_cnt] => 37 [patent_no_of_words] => 120437 [patent_no_of_claims] => 90 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15620391 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14930495 [patent_doc_number] => 20190300885 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-03 [patent_title] => A NOVEL ROLE FOR TERMINAL RNA URIDYLATION AND RNA TURNOVER IN ONCOGENESIS [patent_app_type] => utility [patent_app_number] => 16/308196 [patent_app_country] => US [patent_app_date] => 2017-06-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16165 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16308196 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15360869 [patent_doc_number] => 20200016199 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-16 [patent_title] => METHODS FOR THE TREATMENT OF B CELL MALIGNANCIES USING ADOPTIVE CELL THERAPY [patent_app_type] => utility [patent_app_number] => 16/307462 [patent_app_country] => US [patent_app_date] => 2017-06-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 56989 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -35 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16307462 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12171043 [patent_doc_number] => 09889160 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-02-13 [patent_title] => 'Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene' [patent_app_type] => utility [patent_app_number] => 15/606995 [patent_app_country] => US [patent_app_date] => 2017-05-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 62 [patent_figures_cnt] => 49 [patent_no_of_words] => 37613 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 149 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15606995 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14729147 [patent_doc_number] => 10383954 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-08-20 [patent_title] => Methods of inducing responsiveness to anti-angiogenic agent [patent_app_type] => utility [patent_app_number] => 15/607083 [patent_app_country] => US [patent_app_date] => 2017-05-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 38486 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 82 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15607083 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12171046 [patent_doc_number] => 09889161 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-02-13 [patent_title] => 'Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene' [patent_app_type] => utility [patent_app_number] => 15/607059 [patent_app_country] => US [patent_app_date] => 2017-05-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 62 [patent_figures_cnt] => 49 [patent_no_of_words] => 37615 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 168 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15607059 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15145029 [patent_doc_number] => 20190350992 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-21 [patent_title] => USE OF VIRAL VECTORS IN THE TREATMENT OF RETINOBLASTOMA [patent_app_type] => utility [patent_app_number] => 16/461680 [patent_app_country] => US [patent_app_date] => 2017-05-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10111 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16461680 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12862954 [patent_doc_number] => 20180179492 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-28 [patent_title] => ISOLATION OF NON-EMBRYONIC STEM CELLS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 15/588964 [patent_app_country] => US [patent_app_date] => 2017-05-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 57752 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -36 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15588964 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14277891 [patent_doc_number] => 20190136230 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-09 [patent_title] => GENETICALLY ENGINEERED CELLS AND METHODS OF MAKING THE SAME [patent_app_type] => utility [patent_app_number] => 16/098845 [patent_app_country] => US [patent_app_date] => 2017-05-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 104454 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -373 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16098845 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12023947 [patent_doc_number] => 20170314044 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-02 [patent_title] => 'ADENOVIRUS CONSTRUCTS AND METHODS' [patent_app_type] => utility [patent_app_number] => 15/584394 [patent_app_country] => US [patent_app_date] => 2017-05-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 23 [patent_no_of_words] => 15993 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15584394 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14159213 [patent_doc_number] => 20190106709 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-04-11 [patent_title] => HSV VECTORS WITH ENHANCED REPLICATION IN CANCER CELLS [patent_app_type] => utility [patent_app_number] => 16/095077 [patent_app_country] => US [patent_app_date] => 2017-04-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7747 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16095077 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11992448 [patent_doc_number] => 20170296601 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-10-19 [patent_title] => 'Compositions and Methods for Treating an Immunodeficiency Virus Infection' [patent_app_type] => utility [patent_app_number] => 15/498319 [patent_app_country] => US [patent_app_date] => 2017-04-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 42 [patent_figures_cnt] => 42 [patent_no_of_words] => 31340 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15498319 [rel_patent_id] =>[rel_patent_doc_number] =>)